Immunovant Inc IMVT
NASDAQ · United States · Health Technology
$33.78+0.32 (+0.96%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Immunovant (IMVT) just told the market that its proof-of-concept Phase 2b trial for IMVT-1402 in cutaneous lupus erythematosus missed the primary efficacy goal, and the program in this indication is being discontinued. The mixed trial outcome lands at a sensitive moment for Immunovant. The share price is US$33.49 after a 1-day share price return of 0.57%, yet the 7-day share price return is down 9.92% and the 30-day share price return is down 18.71%. This hints that recent traders have been...
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower. The company reported that its Phase 2b proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve the primary endpoint. The study failed to show a statistically significant difference […]
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.